After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...